keyword
MENU ▼
Read by QxMD icon Read
search

Cervical cancer, ovarian cancer, uterine cancer

keyword
https://www.readbyqxmd.com/read/28708790/trends-of-gynecological-cancers-in-turkey-towards-europe-or-asia
#1
Murat Gultekin, Irem Kucukyildiz, Mujdegul Zayifoglu Karaca, Selin Dundar, Guledal Boztas, Semra Hatice Turan, Ezgi Hacikamiloglu, Bekir Keskinkilic
OBJECTIVE: The aim of this study was to evaluate nationwide gynecological cancer trends in Turkey. METHODS: National cancer registry data (2009-2013) of Turkish Ministry of Health were evaluated. Ovarian, cervical, endometrial, vulvar, vaginal, and tubal cancers are evaluated with respect to age of diagnosis, incidence rates within years, stage, histological distributions, and mortality rates. Data were collected from active cancer registry centers, which increased from 23% in 2009 to 47...
July 13, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28697106/readmission-after-gynecologic-surgery-a-comparison-of-procedures-for-benign-and-malignant-indications
#2
Lori Cory, Nawar Latif, Colleen Brensinger, Xiaochen Zhang, Robert L Giuntoli, Robert A Burger, Mark Morgan, Emily Ko
OBJECTIVE: To compare 30-day postsurgical readmission rates and associated risk factors for readmission among women undergoing gynecologic surgery for benign and malignant conditions. METHODS: In a retrospective cohort study, we identified patients after surgery for benign and malignant gynecologic conditions in the National Surgical Quality Improvement Program database between January 1, 2011, and December 31, 2012. Data collected included surgical factors, perioperative characteristics, surgical complications, and 30-day readmissions...
July 7, 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28641821/insurance-coverage-among-women-diagnosed-with-a-gynecologic-malignancy-before-and-after-implementation-of-the-affordable-care-act
#3
Haley A Moss, Laura J Havrilesky, Junzo Chino
OBJECTIVE: The Patient Protection and Affordable Care Act (ACA) included provisions to expand insurance coverage by expanding Medicaid eligibility, providing subsidies of private coverage and enforcing an individual mandate. The objective of this study is to examine the impact of the ACA on insurance rates among women diagnosed with a gynecologic malignancy. METHODS: Using Surveillance, Epidemiology, and End Results 18 registries database, women newly diagnosed with cervical, uterine or ovarian cancer between 2008 and 2014 were identified...
June 19, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28637507/dysregulated-expression-of-long-noncoding-rnas-in-gynecologic-cancers
#4
REVIEW
Elahe Seyed Hosseini, Matthieu Meryet-Figuiere, Hamed Sabzalipoor, Hamed Haddad Kashani, Hossein Nikzad, Zatollah Asemi
Cancers of the female reproductive system include ovarian, uterine, vaginal, cervical and vulvar cancers, which are termed gynecologic cancer. The emergence of long noncoding RNAs (lncRNAs), which are believed to play a crucial role in several different biological processes, has made the regulation of gene expression more complex. Although the function of lncRNAs is still rather elusive, their broad involvement in the initiation and progression of various cancers is clear. They are also involved in the pathogenesis of cancers of the female reproductive system...
June 21, 2017: Molecular Cancer
https://www.readbyqxmd.com/read/28594645/novel-imaging-techniques-in-gynaecological-cancer
#5
Vincent Vandecaveye, Raphaëla Dresen, Frederik De Keyzer
PURPOSE OF REVIEW: To describe the added value of novel functional MRI techniques towards detection, staging, characterization, response monitoring and prognostication in gynaecological cancer. RECENT FINDINGS: Functional MRI including diffusion-weighted imaging (DWI)-MRI and dynamic contrast-enhanced (DCE)-MRI adds structural, hemodynamic and physiological information to anatomical MRI. In endometrial and cervical cancer, the addition of DWI-MRI and DCE-MRI improves tumour detection as well as staging of uterine and extra-uterine pelvic spread...
June 7, 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/28585840/-postoperative-administration-of-octreotide-to-reduce-lymphorrhea-lymphocele-lymphedema-and-lymphatic-ascites-after-lymphadenectomy-in-gynecological-malignancies
#6
V Weinberger, L Minář, M Felsinger, D Seidlová, P Ovesná, M Bednaříková, E Jandáková, I Rovný
INTRODUCTION: Octreotide is a synthetic analogue of natural somatostatin. Octreotide effect on lymphorrhea reduction in gynecological malignancies has only been assessed in case studies. DESIGN: Original work. SETTING: Gynecologic Oncology Center, Department of Obstetrics and Gynecology, Faculty of Medicine, Masaryk University and University Hospital Brno. METHODS: In 2014 there was a prospective, randomized, one-institution study...
2017: Ceská Gynekologie
https://www.readbyqxmd.com/read/28562469/gynecological-cancer-as-a-second-malignancy-in-patients-with-breast-cancer
#7
Budhi Singh Yadav, Suresh C Sharma, Firuza D Patel, Bhavana Rai, Sushmita Ghoshal
PURPOSE: The aim of this study was to determine the incidence and risk factors for gynecological cancer as second malignancy (SM) after treatment of breast cancer (BC). METHODS AND MATERIALS: Between January 1985 and December 2007, a total of 2756 patients with BC were analyzed for gynecological cancers as an SM. Analysis was carried out for patient-, disease-, and treatment-related characteristics. The Cox proportional hazards regression model was used to estimate the relative risk of gynecologic malignancies...
July 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28537882/correlation-between-apparent-diffusion-coefficient-adc-and-cellularity-is-different-in-several-tumors-a-meta-analysis
#8
Alexey Surov, Hans Jonas Meyer, Andreas Wienke
The purpose of this meta-analysis was to provide clinical evidence regarding relationship between ADC and cellularity in different tumors based on large patient data.Medline library was screened for associations between ADC and cell count in different tumors up to September 2016. Only publications in English were extracted. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA) was used for the research.Overall, 39 publications with 1530 patients were included into the analysis...
May 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/28498261/clear-cell-carcinoma-of-the-uterine-cervix-a-clinical-and-pathological-analysis-of-47-patients-without-intrauterine-diethylstilbestrol-exposure
#9
Li Yang, Aiwen Zheng, Xiang Zhang, Xianhua Fang, Wenyong Sun, Yaqing Chen
OBJECTIVES: The aim of this study was to summarize the clinical and pathological characteristics and to conduct prognosis analysis of patients who were diagnosed with clear cell carcinoma of the uterine cervix (CCCUC) and without a history of exposure to diethylstilbestrol. METHODS: We performed a retrospective review of all the patients with CCCUC who were diagnosed and treated at Zhejiang Cancer Hospital between 1998 and 2014. Charts were reviewed for clinical and pathological characteristics, and prognosis analysis was conducted...
June 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28439056/-calcium-and-bone-metabolism-across-women-s-life-stages-treatment-for-the-malignant-tumors-in-women-and-bone-calcium-metabolism
#10
Noriko Kobayashi
In the malignant tumors in women, uterine cervical cancer, endometrial cancer, ovarian cancer, and breast cancer are representative diseases. The cancer treatment is classified roughly into an operation, medical treatment, and radiation therapy and has an extremely big influence on ovarian function. With the improvement in survival of cancer patients, the importance of the health care for the cancer survivors increases. It is necessary to prevent the onset of the osteoporotic fractures to maintain QOL. This paper describes the action that the malignant tumors of the women affect bone metabolism mainly from the viewpoint of ovarian function...
2017: Clinical Calcium
https://www.readbyqxmd.com/read/28382802/major-clinical-research-advances-in-gynecologic-cancer-in-2016-10-year-special-edition
#11
REVIEW
Dong Hoon Suh, Miseon Kim, Kidong Kim, Hak Jae Kim, Kyung Hun Lee, Jae Weon Kim
In 2016, 13 topics were selected as major research advances in gynecologic oncology. For ovarian cancer, study results supporting previous ones regarding surgical preventive strategies were reported. There were several targeted agents that showed comparable responses in phase III trials, including niraparib, cediranib, and nintedanib. On the contrary to our expectations, dose-dense weekly chemotherapy regimen failed to prove superior survival outcomes compared with conventional triweekly regimen. Single-agent non-platinum treatment to prolong platinum-free-interval in patients with recurrent, partially platinum-sensitive ovarian cancer did not improve and even worsened overall survival (OS)...
May 2017: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/28326512/tissue-expression-of-human-epididymal-secretory-protein-4-may-be-useful-in-the-differential-diagnosis-of-uterine-cervical-tumors
#12
Gulden Diniz, Tugba Karadeniz, Sevil Sayhan, Talya Akata, Fatma Aydiner, Duygu Ayaz, Dudu Solakoglu Kahraman, Tulay Akman
OBJECTIVES: Human Epididymal Secretory Protein 4 was firstly described as an epididymis-specific protein but more recently it has been demonstrated to be a putative serum tumor marker for different malignancies, especially ovarian epithelial cancers. The aim of this study is to investigate the association between tissue Human Epididymal Secretory Protein 4 expression and the clinicopathological features of uterine cervical tumors. MATERIAL AND METHODS: This retrospective study was designed to evaluate the differences of tissue expressions of Human Epididymal Secretory Protein 4 protein in a spectrum of cervical neoplasms...
2017: Ginekologia Polska
https://www.readbyqxmd.com/read/28303492/contributions-of-the-japanese-gynecologic-oncology-group-jgog-in-improving-the-quality-of-life-in-women-with-gynecological-malignancies
#13
REVIEW
Masayuki Futagami, Yoshihito Yokoyama, Muneaki Shimada, Shinya Sato, Etsuko Miyagi, Akiko Tozawa-Ono, Nao Suzuki, Masaki Fujimura, Yoichi Aoki, Satoru Sagae, Toru Sugiyama
The Japanese Gynecologic Oncology Group (JGOG) is leading Japan in the treatment of gynecological malignancies. The JGOG consists of three treatment committees focusing on uterine cervical cancer, endometrial cancer, and ovarian cancer. Each committee makes efforts to improve treatment and diagnosis. In addition, the Supportive and Palliative Care Committee was established in 2015. Novel studies of supportive care and palliative care have been initiated by this committee. Furthermore, surveys about not only treatment results such as overall survival rates but also quality of life (QOL) and cost-effectiveness assessments are performed by the ovarian cancer committee...
April 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28275696/surgical-management-of-squamous-cell-vulvar-cancer-without-clitoris-urethra-or-anus-involvement
#14
REVIEW
Alpaslan Kaban, Işık Kaban, Selim Afşar
Vulvar cancers, which constitute 5% of all gynecologic cancers, are the fourth most common female genital cancers, preceded by uterine, ovarian and cervical cancers. The treatment methods employed for vulvar cancers have changed over the years, with previously applied radical surgical approaches, such as en bloc resection, being gradually suspended in favor of treatment approaches that require dissection of less tissue. While the removal of less tissue, which today's approaches have focused on, prevents morbidity, this method seems to result in higher risks of recurrence...
May 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/28202331/genetics-of-gynaecological-cancers
#15
REVIEW
Panayiotis Constantinou, Marc Tischkowitz
Gynaecological cancers accounted for 16.3% of all cancers and 13.9% of all cancer deaths in women globally in 2012. Cancer of the cervix is the most common gynaecological cancer, followed by cancers of the uterus and the ovary. Although cervical cancer is almost exclusively triggered by human papilloma virus infection, approximately 5% of all uterine cancers and 20% of all ovarian cancers are caused by germline mutations in cancer predisposition genes. A number of genetic syndromes are associated with rarer gynaecological tumours...
July 2017: Best Practice & Research. Clinical Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/28187092/incidence-of-venous-thromboembolism-by-type-of-gynecologic-malignancy-and-surgical-modality-in-the-national-surgical-quality-improvement-program
#16
Ashley Graul, Nawar Latif, Xiaochen Zhang, Lorraine T Dean, Mark Morgan, Robert Giuntoli, Robert Burger, Sarah Kim, Emily Ko
BACKGROUND: Women with gynecologic cancer are at higher risk of venous thromboembolism (VTE) due to malignancy, pelvic surgery, increased age, and frequently comorbidities. The rate of VTE among different gynecologic cancers and relative to benign gynecologic surgeries has not been reported in a nationally representative cohort. METHODS: Using the American College of Surgeons National Surgical Quality Improvement Program database, gynecologic surgeries were identified retrospectively from 2006 to 2012...
March 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28156638/rolapitant-for-control-of-chemotherapy-induced-nausea-and-vomiting-cinv-in-patients-with-gynecologic-cancer
#17
Lee Steven Schwartzberg, Sujata Arora, Daniel Powers, Karin Jordan, Rudolph M Navari
223 Background: Rolapitant, a long-acting neurokinin-1 receptor antagonist, protected against CINV in patients receiving highly or moderately emetogenic chemotherapy (HEC or MEC). METHODS: In 3 double-blind phase 3 studies, patients were randomized to receive oral rolapitant 180 mg or placebo before administration of HEC or MEC. All patients received a 5-hydroxytryptamine type 3 receptor antagonist and dexamethasone. In a post hoc analysis of 3 pooled studies (2 HEC and 1 MEC), we assessed the efficacy and safety of rolapitant in patients with gynecologic (ovarian, uterine, or cervical) cancer...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28118455/trends-and-patterns-of-disparities-in-cancer-mortality-among-us-counties-1980-2014
#18
Ali H Mokdad, Laura Dwyer-Lindgren, Christina Fitzmaurice, Rebecca W Stubbs, Amelia Bertozzi-Villa, Chloe Morozoff, Raghid Charara, Christine Allen, Mohsen Naghavi, Christopher J L Murray
Introduction: Cancer is a leading cause of morbidity and mortality in the United States and results in a high economic burden. Objective: To estimate age-standardized mortality rates by US county from 29 cancers. Design and Setting: Deidentified death records from the National Center for Health Statistics (NCHS) and population counts from the Census Bureau, the NCHS, and the Human Mortality Database from 1980 to 2014 were used. Validated small area estimation models were used to estimate county-level mortality rates from 29 cancers: lip and oral cavity; nasopharynx; other pharynx; esophageal; stomach; colon and rectum; liver; gallbladder and biliary; pancreatic; larynx; tracheal, bronchus, and lung; malignant skin melanoma; nonmelanoma skin cancer; breast; cervical; uterine; ovarian; prostate; testicular; kidney; bladder; brain and nervous system; thyroid; mesothelioma; Hodgkin lymphoma; non-Hodgkin lymphoma; multiple myeloma; leukemia; and all other cancers combined...
January 24, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28088330/genomic-insights-in-gynecologic-cancer
#19
Erika Roddy, Jocelyn Chapman
Recent technological advances in DNA sequencing have enabled a remarkably detailed understanding of the molecular changes that define gynecologic and other cancers. Several groups have carried out large-scale genomic analyses of ovarian, uterine, and most recently, cervical cancer. These analyses have led to new insights into the molecular changes characterizing these cancers, which provide insight into clinical outcomes. These molecular characterizations have similarly led to new genomic-based classification schemas, which may better stratify clinical outcomes, help prognosticate and guide treatments...
January 2017: Current Problems in Cancer
https://www.readbyqxmd.com/read/28001084/resveratrol-as-an-anticancer-agent-a-review
#20
Abdur Rauf, Muhammad Imran, Masood Sadiq Butt, Muhammad Nadeem, Dennis G Peters, Mohammad S Mubarak
Owing to their antimicrobial, antioxidant, and anti-inflammatory activity, grapes (Vitis vinifera L.) are the archetypal paradigms of fruits used not only for nutritional purposes but also for exclusive therapeutics. Grapes are a prominent and promising source of phytochemicals, especially resveratrol, a phytoalexin antioxidant found in red grapes which has both chemopreventive and therapeutic effects against various ailments. Resveratrol's role in reducing different human cancers, including breast, cervical, uterine, blood, kidney, liver, eye, bladder, thyroid, esophageal, prostate, brain, lung, skin, gastric, colon, head and neck, bone, ovarian, and cervical, has been reviewed...
December 21, 2016: Critical Reviews in Food Science and Nutrition
keyword
keyword
34723
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"